ホーム › トリプルネガティブ乳がん › ニューヨーク

ニューヨークにおけるトリプルネガティブ乳がんの臨床試験

ニューヨーク内の拠点で、トリプルネガティブ乳がんに関する46件の研究が参加者を募集しています。

ニューヨーク内の都市

公式研究テキスト（英語）

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

START New York Long Island LLC, Lake Success

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
Icahn School of Medicine at Mount Sinai, New York
他2件

被験者募集中第1相

18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Columbia University Medical Center, New York
Memorial Sloan Kettering, New York

被験者募集中第1/2相

12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

NYU Langone Hospital - Long Island, Mineola
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/30更新 · NCT05422794

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NYU Longone Health (Long Island), Long Island City
NYU Longone Health (Manhattan), Manhattan

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/29更新 · NCT06799065

Study of AVZO-021 in Patients With Advanced Solid Tumors

Avenzo Therapeutics Recruiting Site, Mineola
Avenzo Therapeutics Recruiting Site, New York

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/28更新 · NCT05867251

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NYU Langone Medical Center, New York

被験者募集中観察研究

18歳以上 · 全性別 · 2026/09/25更新 · NCT04981119

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0073), Mineola
Laura and Isaac Perlmutter Cancer Center ( Site 0003), New York

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06841354

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0135), New York
Icahn School of Medicine at Mount Sinai ( Site 0123), New York
Memorial Sloan Kettering Cancer Center ( Site 0067), New York
他1件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/25更新 · NCT06393374

Intratumoral N17350 in Advanced Solid Tumors

Roswell Park Comprehensive Cancer Center, Buffalo

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/23更新 · NCT07339176

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Memorial Sloan Kettering Cancer Center Head Neck Services, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Icahn School of Medicine at Mt. Sinai, New York
Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/17更新 · NCT07020117

A Study of Pembrolizumab and Ablation (Cryoablation or Histotripsy) in People With Breast Cancer

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ), Commack
Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All protocol activites), New York
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/14更新 · NCT06246968

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

Mount Sinai, New York

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/09/11更新 · NCT06657222

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Memorial Sloan Kettering Suffolk - Commack (All Protocol Activities), Commack
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/09更新 · NCT05570253

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NYP/Weill Cornell Medical Center, New York

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/09更新 · NCT03606967

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Hematology Oncology Associates of Central New York, PC, East Syracuse
Northwell Health, Lake Success
Laura and Isaac Perlmutter Cancer Canter, New York
他5件

被験者募集中第3相

18歳以上 · 全性別 · 2026/09/09更新 · NCT05633654

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

NYU Langone Health - Long Island, Mineola
New York University (NYU) Clinical Cancer Center, New York
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1相

18歳以上 · 全性別 · 2026/09/04更新 · NCT06400472

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Roswell Park Comprehensive Cancer Center, Buffalo

被験者募集中第2相

18歳以上 · 全性別 · 2026/09/03更新 · NCT05846789

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

SUNY Upstate Medical University, Syracuse

被験者募集中第2相

18歳以上 · 全性別 · 2026/08/24更新 · NCT07743190

A Study of Cyclophosphamide, Methotrexate, Fluorouracil (CMF) for People With Breast Cancer

Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack
Memorial Sloan Kettering at Westchester (Limited Protocol Activities), Harrison
Memorial Sloan-Kettering Cancer Center (All Protocol Activities), New York
他1件

被験者募集中第2相

70歳以上 · 全性別 · 2026/08/17更新 · NCT07768436

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Memorial Sloan Kettering Cancer Center, New York

被験者募集中第1/2相

18歳以上 · 全性別 · 2026/08/13更新 · NCT05985655

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Memorial Sloan Kettering Cancer Center, New York
Local Institution - 1037, Syracuse
Clinical Research Alliance, Westbury
他1件

被験者募集中第2/3相

18歳以上 · 全性別 · 2026/08/10更新 · NCT06926868

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Roswell Park Cancer Institute, Buffalo

被験者募集中第1相

18歳以上 · 全性別 · 2026/07/28更新 · NCT06150664

A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center - Investigational Drug Service Pharmacy, Long Island City
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street)., New York
Memorial Sloan Kettering Cancer Center 53rd street., New York
他1件

被験者募集中第1相

18歳以上 · 全性別 · 2026/07/22更新 · NCT07318805